Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 11/20 | 0.70 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.70 |
| ▸ | KDR | P35968 | 3/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.49 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.47 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.46 |
| ▸ | ATR | Q13535 | 1/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29358505 | 1.00 | TGFBR1 (0.70) | TGFBR1MAPK14KDRGABRA5ITGA5 | |
| Water SCHEMBL29649719 | 0.99 | TGFBR1 (0.69) | TGFBR1MAPK14KDRGABRA5ITGA5 | |
| Water SCHEMBL29649721 | 0.99 | TGFBR1 (0.69) | TGFBR1MAPK14KDRGABRA5ITGA5 | |
| Water SCHEMBL21633982 | 0.99 | TGFBR1 (0.69) | TGFBR1MAPK14KDRGABRA5ITGA5 | |
| SCHEMBL12444984 | 0.91 | TGFBR1 (0.57) | TGFBR1MAPK14MAPKAPK2EGLN1DYRK1B | |
| SCHEMBL6198505 | 0.89 | TGFBR1 (0.56) | TGFBR1MAPK14KDRGABRA5ITGA5 | |
| SCHEMBL5907455 | 0.89 | TGFBR1 (0.67) | TGFBR1MAPK14KDRGABRA5ITGA5 | |
| SCHEMBL461877 | 0.88 | TGFBR1 (0.53) | TGFBR1MAPK14GABRA5ITGA5EGLN1 | |
| SCHEMBL29541278 | 0.88 | TGFBR1 (0.53) | TGFBR1MAPK14GABRA5ITGA5EGLN1 | |
| SCHEMBL6179158 | 0.87 | TGFBR1 (0.53) | TGFBR1MAPK14GABRA5EGLN1ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 377 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025097221-A1 | OPTIMIZED METHOD FOR GENERATING HUMAN SKIN ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | THE UNIVERSITY OF QUEENSLAND (AU) | 2025-05-15 | — | — | WO | claimed |
| EP-4416268-A1 | METHODS FOR PRODUCING CARTILAGE AND BONES | Murdoch Children's Research Institute (AU) | 2024-08-21 | — | — | EP | claimed |
| US-12065671-B2 | Method for reproducible differentiation of clinical-grade retinal pigment epithelium cells | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-08-20 | — | — | US | claimed |
| US-20240271089-A1 | METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS | THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-08-15 | — | — | US | claimed |
| EP-4347795-A1 | METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2024-04-10 | — | — | EP | claimed |
| EP-4345160-A2 | METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2024-04-03 | — | — | EP | claimed |
| EP-3384007-B1 | IMPROVED METHODS FOR REPROGRAMING NON-PLURIPOTENT CELLS INTO PLURIPOTENT STEM CELLS | BEIHAO STEM CELL AND REGENERATIVE MEDICINE RES INSTITUTE CO LTD (CN) | 2024-03-27 | — | — | EP | claimed |
| CN-114807035-B | Reproducible differentiation method of clinical grade retinal pigment epithelial cells | (由卫生与公众服务部部长代表的)美利坚合众国 | 2024-02-02 | — | — | CN | claimed |
| EP-3347456-B1 | METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS | US HEALTH (US) | 2023-12-27 | — | — | EP | claimed |
| US-20230151336-A1 | STEM CELL DERIVED SINGLE-ROSETTE BRAIN ORGANOIDS AND RELATED USES THEROF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-05-18 | — | — | US | claimed |
| EP-3347456-A1 | METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2018-07-18 | — | — | EP | claimed |
| EP-3307874-A1 | DERIVATION OF HEPATIC STEM CELLS AND MATURE LIVER CELL TYPES AND USES THEREOF | Agency For Science, Technology And Research (SG) | 2018-04-18 | — | — | EP | claimed |
| WO-2017044483-A1 | METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-03-16 | — | — | WO | claimed |
| WO-2016200340-A1 | DERIVATION OF HEPATIC STEM CELLS AND MATURE LIVER CELL TYPES AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-12-15 | — | — | WO | claimed |
| WO-2016029267-A1 | A METHOD FOR CULTURING MESENCHYMAL STEM CELLS | PRINCE HENRY'S INSTITUTE OF MEDICAL RESEARCH TRADING AS THE HUDSON INSTITUTE OF MEDICAL RESEARCH (AU) | 2016-03-03 | — | — | WO | claimed |
| US-20090181420-A1 | Inhibiting Smad signaling promotes neuron regeneration | CHILDREN'S MEDICAL CENTER CORPORATION | 2009-07-16 | — | — | US | claimed |
| EP-1355903-B1 | PYRAZOLE DERIVATIVES AGAINST TGF OVEREXPRESSION | SMITHKLINE BEECHAM CORP (US) | 2005-03-16 | — | — | EP | claimed |
| US-20040087623-A1 | Pyrazole derivatives against tgf overexpression | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | US | claimed |
| EP-1355903-A1 | PYRAZOLE DERIVATIVES AGAINST TGF OVEREXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-29 | — | — | EP | claimed |
| WO-2002066462-A1 | PYRAZOLE DERIVATIVES AGAINST TGF OVEREXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-08-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087623-A1 | Pyrazole derivatives against tgf overexpression | TGFBR1, SMAD3, TGFBR2 | TGFBR1 1/4885MAPK14 1348/4885KDR 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.